metformin has been researched along with fluoxetine in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 16 (57.14) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sanders, TA; Taylor, D; Werneke, U | 1 |
| Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL | 1 |
| Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A | 1 |
| Cesarino, EJ; de Almeida, CA; de Carvalho, D; Guimarães, C; Iucif Júnior, N; Pereira, LR; Queiroz, RH | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Hashemipour, M; Kelishadi, R; Poursafa, P; Rezvanian, H; Tavakoli, N | 1 |
| Ayuob, N; Murad, H | 1 |
| Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B | 1 |
| Aswar, M; Aswar, U; Chepurwar, S; Shintre, S | 1 |
| Abd-Alkhalek, HA; Aboul-Fotouh, S; El-Kharashi, OA; Elmelgy, AA; Khedr, SA; Louka, ML; Sallam, HA | 1 |
| Alboni, S; Branchi, I; Brunello, N; Golia, MT; Limatola, C; Maggi, L; Matte Bon, G; Milior, G; Poggini, S; Puglisi-Allegra, S; Sciarria, LP; Viglione, A | 1 |
| Combarnous, Y; Filliatreau, L; Klett, D; Nguyen, TMD | 1 |
| Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J | 1 |
| Costa, BLDSAD; Duarte-Silva, EP; Melo, MG; Mendonça, IP; Oliveira, WH; Paiva, IHR; Peixoto, CA; Silva, RSD | 1 |
| Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH | 1 |
| Boiani, NF; Borrely, SI; Garcia, VSG; Silva, TT; Tominaga, FK | 1 |
| Feng, JH; Inci, G; Jung, JS; Kang, BG; Kim, JH; Kim, SB; Kim, SC; Lee, JY; Lim, SS; Mo, YW; Park, SH; Seo, JH; Shende, M; Suh, HW | 1 |
6 review(s) available for metformin and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain | 2002 |
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone | 2002 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
Drug interventions for the treatment of obesity in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; Metformin; Orlistat; Pediatric Obesity; Randomized Controlled Trials as Topic | 2016 |
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Nizatidine; Ranitidine; Reboxetine; Schizophrenia; Topiramate; Weight Gain | 2022 |
3 trial(s) available for metformin and fluoxetine
| Article | Year |
|---|---|
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypoglycemic Agents; Metformin; Obesity; Pilot Projects; Prospective Studies; Treatment Outcome; Weight Loss | 2007 |
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressants; Cholesterol; Combined Modality Therapy; Cyclobutanes; Fluoxetine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Placebos; Single-Blind Method | 2006 |
A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metformin; Obesity | 2010 |
19 other study(ies) available for metformin and fluoxetine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Co-Administration of Pioglitazone Improves Fluoxetine's Antinociceptive, Neuroprotective, and Antidepressant Effects in Chronic Constriction Injury in Rats.
Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Chronic Pain; Constriction, Pathologic; Cytokines; Fluoxetine; Hyperalgesia; Hypoglycemic Agents; Male; Metformin; Neuroprotective Agents; Pioglitazone; Postural Balance; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Spinal Cord; Swimming; Thiazolidinediones | 2015 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depression; Depressive Disorder; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Fluoxetine; Hydrocortisone; Interleukin-1beta; Interleukin-6; Male; Metformin; Nitric Oxide; Pilot Projects; Rats; Rats, Wistar; Renin-Angiotensin System; Streptozocin; Swimming; Telmisartan | 2017 |
Metformin potentiates cognitive and antidepressant effects of fluoxetine in rats exposed to chronic restraint stress and high fat diet: potential involvement of hippocampal c-Jun repression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Diet, High-Fat; Drug Synergism; Fluoxetine; Hippocampus; Hypoglycemic Agents; Male; Metformin; Proto-Oncogene Proteins c-jun; Rats, Wistar; Restraint, Physical; Stress, Psychological | 2018 |
Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus.
Topics: Anhedonia; Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Drug Therapy, Combination; Fluoxetine; Hippocampus; Hypoglycemic Agents; Insulin-Like Growth Factor II; Male; Metformin; Mice; Selective Serotonin Reuptake Inhibitors | 2019 |
Inhibition by fluoxetine of LH-stimulated cyclic AMP synthesis in tumor Leydig cells partly involves AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Colforsin; Cyclic AMP; Enzyme Activation; Fluoxetine; Leydig Cells; Luteinizing Hormone; Male; Metformin; Mice | 2019 |
Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Depression; Diabetes Mellitus, Type 2; Disease Models, Animal; Fluoxetine; Hippocampus; Histones; Male; Metformin; Mice; Mice, Inbred C57BL; Stress, Psychological; Swimming | 2020 |
Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity.
Topics: Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Depression; Drug Therapy, Combination; Fluorescent Antibody Technique; Fluoxetine; Hindlimb Suspension; Hippocampus; Male; Metformin; Mice; Mice, Inbred C57BL; Neurogenesis; Neuroinflammatory Diseases; Neuronal Plasticity; Parkinsonian Disorders; Prefrontal Cortex; Rotarod Performance Test | 2022 |
Acute and chronic ecotoxicological effects of pharmaceuticals and their mixtures in Daphnia similis.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Ciprofloxacin; Daphnia; Fluoxetine; Hypoglycemic Agents; Metformin; Pharmaceutical Preparations; Water; Water Pollutants, Chemical | 2022 |
Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Fluoxetine; HCT116 Cells; Humans; Metformin; Mice; Mice, Nude; Neoplasms; Reactive Oxygen Species; Signal Transduction | 2023 |